106 related articles for article (PubMed ID: 9447824)
1. The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells.
Berkovic D; Fleer EA; Breass J; Pförtner J; Schleyer E; Hiddemann W
Leukemia; 1997 Dec; 11(12):2079-86. PubMed ID: 9447824
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Horber DH; Schott H; Schwendener RA
Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
[TBL] [Abstract][Full Text] [Related]
3. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
5. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
Ross DD; Joneckis CC; Song TH; Wu RK
Cancer Res; 1988 Feb; 48(3):517-21. PubMed ID: 3335018
[TBL] [Abstract][Full Text] [Related]
6. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
7. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
8. Resistance of human leukemic cell lines to 1-beta-D-arabinofuranosylcytosine: characterization of an experimental model.
Gariboldi MB; Ravizza R; Marras E; Perletti G; De Simone A; Piccinini F; Monti E
Int J Oncol; 2001 Jun; 18(6):1245-9. PubMed ID: 11351258
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
10. Intracellular pharmacodynamics of ara-C and flowcytometric analysis of cell cycle progression in leukemia chemotherapy.
Nakamura T; Takauji R; Kamiya K; Kawai Y; Iwasaki H; Tohyama K; Yamauchi T; Ueda T
Leukemia; 1997 Apr; 11 Suppl 3():548-51. PubMed ID: 9209453
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
[TBL] [Abstract][Full Text] [Related]
12. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
[TBL] [Abstract][Full Text] [Related]
13. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
14. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.
Freund A; Boos J; Harkin S; Schultze-Mosgau M; Veerman G; Peters GJ; Gescher A
Eur J Cancer; 1998 May; 34(6):895-901. PubMed ID: 9797704
[TBL] [Abstract][Full Text] [Related]
16. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
17. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
Jarvis WD; Fornari FA; Tombes RM; Erukulla RK; Bittman R; Schwartz GK; Dent P; Grant S
Mol Pharmacol; 1998 Nov; 54(5):844-56. PubMed ID: 9804619
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Grant S; Turner A; Nelms P; Yanovich S
Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
20. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
